{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T04:40:02Z","timestamp":1789620002944,"version":"build-2803163510"},"reference-count":83,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,10,13]],"date-time":"2016-10-13T00:00:00Z","timestamp":1476316800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Basic to Translational Science"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1016\/j.jacbts.2016.10.001","type":"journal-article","created":{"date-parts":[[2016,12,26]],"date-time":"2016-12-26T16:17:41Z","timestamp":1482769061000},"page":"557-567","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":51,"title":["Innovative Therapeutics"],"prefix":"10.1016","volume":"1","author":[{"given":"Laura M.G.","family":"Meems","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"John C.","family":"Burnett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacbts.2016.10.001_bib1","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1001\/jamacardio.2016.1326","article-title":"Recent trends in cardiovascular mortality in the United States and public health goals","volume":"1","author":"Sidney","year":"2016","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacbts.2016.10.001_bib2","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacbts.2016.10.001_bib3","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1093\/eurheartj\/ehs262","article-title":"Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics","volume":"34","author":"Mangiafico","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacbts.2016.10.001_bib4","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(09)61966-8","article-title":"Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study","volume":"375","author":"Ruilope","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jacbts.2016.10.001_bib5","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1161\/CIRCRESAHA.113.300215","article-title":"Protein engineering for cardiovascular therapeutics: untapped potential for cardiac repair","volume":"113","author":"Jay","year":"2013","journal-title":"Circ Res"},{"key":"10.1016\/j.jacbts.2016.10.001_bib6","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.drudis.2014.10.003","article-title":"Peptide therapeutics: current status and future directions","volume":"20","author":"Fosgerau","year":"2015","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.jacbts.2016.10.001_bib7","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacbts.2016.10.001_bib8","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.drudis.2014.09.017","article-title":"Therapeutic applications of the cell-penetrating HIV-1 Tat peptide","volume":"20","author":"Rizzuti","year":"2015","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.jacbts.2016.10.001_bib9","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(12)61855-8","article-title":"Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial","volume":"381","author":"Teerlink","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jacbts.2016.10.001_bib10","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1056\/NEJM199807303390507","article-title":"Natriuretic peptides","volume":"339","author":"Levin","year":"1998","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacbts.2016.10.001_bib11","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1172\/JCI59701","article-title":"Cardiac natriuretic peptides act via p38 MAPK to induce the brown fat thermogenic program in mouse and human adipocytes","volume":"122","author":"Bordicchia","year":"2012","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jacbts.2016.10.001_bib12","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.jacc.2011.05.011","article-title":"A\u00a0genetic variant of the atrial natriuretic peptide gene is associated with cardiometabolic protection in the general community","volume":"58","author":"Cannone","year":"2011","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacbts.2016.10.001_bib13","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1056\/NEJMcibr1204796","article-title":"The natriuretic peptides and fat metabolism","volume":"367","author":"Wang","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacbts.2016.10.001_bib14","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.amjcard.2007.11.012","article-title":"Biology of the natriuretic peptides","volume":"101","author":"Martinez-Rumayor","year":"2008","journal-title":"Am J Cardiol"},{"issue":"Suppl 1","key":"10.1016\/j.jacbts.2016.10.001_bib15","first-page":"S9","article-title":"The evolution of the natriuretic peptides - current applications in human and animal medicine","volume":"11","author":"van Kimmenade","year":"2009","journal-title":"J\u00a0Vet Cardiol"},{"key":"10.1016\/j.jacbts.2016.10.001_bib16","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1210\/er.2005-0014","article-title":"Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions","volume":"27","author":"Potter","year":"2006","journal-title":"Endocr Rev"},{"key":"10.1016\/j.jacbts.2016.10.001_bib17","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.yfrne.2007.05.001","article-title":"A\u00a0'reverse' phylogenetic approach for identification of novel osmoregulatory and cardiovascular hormones in vertebrates","volume":"28","author":"Takei","year":"2007","journal-title":"Front Neuroendocrinol"},{"key":"10.1016\/j.jacbts.2016.10.001_bib18","doi-asserted-by":"crossref","first-page":"9395","DOI":"10.1016\/S0021-9258(19)76554-5","article-title":"Atrial natriuretic peptide clearance receptor. Complete sequence and functional expression of cDNA clones","volume":"263","author":"Fuller","year":"1988","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jacbts.2016.10.001_bib19","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.peptides.2004.09.023","article-title":"Natriuretic peptide receptor-C signaling and regulation","volume":"26","author":"Anand-Srivastava","year":"2005","journal-title":"Peptides"},{"key":"10.1016\/j.jacbts.2016.10.001_bib20","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1242\/dev.100370","article-title":"Differential activation of natriuretic peptide receptors modulates cardiomyocyte proliferation during development","volume":"141","author":"Becker","year":"2014","journal-title":"Development"},{"key":"10.1016\/j.jacbts.2016.10.001_bib21","doi-asserted-by":"crossref","first-page":"4039","DOI":"10.1172\/JCI74281","article-title":"Endothelial C-type natriuretic peptide maintains vascular homeostasis","volume":"124","author":"Moyes","year":"2014","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jacbts.2016.10.001_bib22","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1161\/01.RES.0000094745.28948.4D","article-title":"Structure, regulation, and function of mammalian membrane guanylyl cyclase receptors, with a focus on guanylyl cyclase-A","volume":"93","author":"Kuhn","year":"2003","journal-title":"Circ Res"},{"key":"10.1016\/j.jacbts.2016.10.001_bib23","first-page":"F863","article-title":"Effects of synthetic atrial natriuretic factor on renal function and renin release","volume":"247","author":"Burnett","year":"1984","journal-title":"Am J Physiol"},{"key":"10.1016\/j.jacbts.2016.10.001_bib24","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1161\/CIRCULATIONAHA.107.759241","article-title":"Chronic actions of a novel oral B-type natriuretic peptide conjugate in normal dogs and acute actions in angiotensin II-mediated hypertension","volume":"118","author":"Cataliotti","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.jacbts.2016.10.001_bib25","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1161\/CIRCHEARTFAILURE.113.000885","article-title":"Atrial natriuretic peptide locally counteracts the deleterious effects of cardiomyocyte mineralocorticoid receptor activation","volume":"7","author":"Nakagawa","year":"2014","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacbts.2016.10.001_bib26","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1007\/BF01726570","article-title":"Isolation and structural analysis of \u201curodilatin\u201d, a new peptide of the cardiodilatin-(ANP)-family, extracted from human urine","volume":"66","author":"Schulz-Knappe","year":"1988","journal-title":"Klinische Wochenschrift"},{"key":"10.1016\/j.jacbts.2016.10.001_bib27","first-page":"715","article-title":"Pro-atrial natriuretic peptide: a novel guanylyl cyclase-A receptor activator that goes beyond atrial and B-type natriuretic peptides","volume":"3","author":"Ichiki","year":"2015","journal-title":"J\u00a0Am Coll Cardiol HF"},{"key":"10.1016\/j.jacbts.2016.10.001_bib28","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1111\/j.1527-5299.2002.01154.x","article-title":"\u201cBNP\u201d for heart failure: role of nesiritide in cardiovascular therapeutics","volume":"8","author":"Mills","year":"2002","journal-title":"Congest Heart Fail"},{"key":"10.1016\/j.jacbts.2016.10.001_bib29","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1161\/CIRCHEARTFAILURE.112.000289","article-title":"Renin-angiotensin blockade combined with natriuretic peptide system augmentation: novel therapeutic concepts to combat heart failure","volume":"6","author":"von Lueder","year":"2013","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacbts.2016.10.001_bib30","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1161\/CIRCHEARTFAILURE.114.001174","article-title":"Pro-B-type natriuretic peptide-1-108 processing and degradation in human heart failure","volume":"8","author":"Huntley","year":"2015","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacbts.2016.10.001_bib31","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1056\/NEJMoa020233","article-title":"Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure","volume":"347","author":"Maisel","year":"2002","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacbts.2016.10.001_bib32","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1093\/eurheartj\/ehi631","article-title":"NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study","volume":"27","author":"Januzzi","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacbts.2016.10.001_bib33","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1016\/j.jacc.2010.01.031","article-title":"The prognostic value of N-terminal pro-B-type natriuretic peptide for death and cardiovascular events in healthy normal and stage A\/B heart failure subjects","volume":"55","author":"McKie","year":"2010","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacbts.2016.10.001_bib34","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.peptides.2016.01.004","article-title":"Cardiorenal fibrosis and dysfunction in aging: imbalance in mediators and regulators of collagen","volume":"76","author":"Sangaralingham","year":"2016","journal-title":"Peptides"},{"key":"10.1016\/j.jacbts.2016.10.001_bib35","doi-asserted-by":"crossref","first-page":"13928","DOI":"10.1016\/S0021-9258(19)49658-0","article-title":"A\u00a0new member of the natriuretic peptide family is present in the venom of the green mamba (Dendroaspis angusticeps)","volume":"267","author":"Schweitz","year":"1992","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jacbts.2016.10.001_bib36","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ejheart.2005.04.012","article-title":"Epidemiology of heart failure in a community-based study of subjects aged > or\u00a0= 57 years: incidence and long-term survival","volume":"8","author":"van Jaarsveld","year":"2006","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacbts.2016.10.001_bib37","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/j.jacc.2012.05.049","article-title":"Human hypertension is characterized by a lack of activation of the antihypertensive cardiac hormones ANP and BNP","volume":"60","author":"Macheret","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacbts.2016.10.001_bib38","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1007\/s11906-011-0244-5","article-title":"M-atrial natriuretic peptide: a novel antihypertensive protein therapy","volume":"14","author":"McKie","year":"2012","journal-title":"Curr Hyperten Rep"},{"key":"10.1016\/j.jacbts.2016.10.001_bib39","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/S0002-9149(96)00464-X","article-title":"Hemodynamic effects of a single intravenous injection of synthetic human brain natriuretic peptide in patients with heart failure secondary to ischemic or idiopathic dilated cardiomyopathy","volume":"78","author":"Hobbs","year":"1996","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacbts.2016.10.001_bib40","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1056\/NEJM200007273430403","article-title":"Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group","volume":"343","author":"Colucci","year":"2000","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacbts.2016.10.001_bib41","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1001\/jama.293.15.1900","article-title":"Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials","volume":"293","author":"Sackner-Bernstein","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.jacbts.2016.10.001_bib42","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1161\/01.CIR.0000159340.93220.E4","article-title":"Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure","volume":"111","author":"Sackner-Bernstein","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.jacbts.2016.10.001_bib43","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1100171","article-title":"Effect of nesiritide in patients with acute decompensated heart failure","volume":"365","author":"O'Connor","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacbts.2016.10.001_bib44","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1161\/CIRCULATIONAHA.113.003046","article-title":"Nesiritide, renal function, and associated outcomes during hospitalization for acute decompensated heart failure: results from the Acute Study of Clinical Effectiveness of Nesiritide and Decompensated Heart Failure (ASCEND-HF)","volume":"130","author":"van Deursen","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.jacbts.2016.10.001_bib45","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1001\/jama.2013.282190","article-title":"Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial","volume":"310","author":"Chen","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.jacbts.2016.10.001_bib46","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1161\/CIRCULATIONAHA.110.981720","article-title":"Long-term cardiac pro-B-type natriuretic peptide gene delivery prevents the development of hypertensive heart disease in spontaneously hypertensive rats","volume":"123","author":"Cataliotti","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.jacbts.2016.10.001_bib47","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/ejhf.468","article-title":"Chronic subcutaneous brain natriuretic peptide therapy in asymptomatic systolic heart failure","volume":"18","author":"McKie","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacbts.2016.10.001_bib48","first-page":"539","article-title":"Chronic peptide therapy with B-Type Natriuretic peptide in patients with pre-clinical diastolic dysfunction (stage B heart failure)","volume":"4","author":"Wan","year":"2016","journal-title":"J\u00a0Am Coll Cardiol HF"},{"key":"10.1016\/j.jacbts.2016.10.001_bib49","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1016\/j.jacc.2012.07.056","article-title":"Novel protein therapeutics for systolic heart failure: chronic subcutaneous B-type natriuretic peptide","volume":"60","author":"Chen","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacbts.2016.10.001_bib50","first-page":"262","article-title":"Roles of atrial natriuretic peptide and its therapeutic use","volume":"56","author":"Saito","year":"2010","journal-title":"J\u00a0Cardiol"},{"key":"10.1016\/j.jacbts.2016.10.001_bib51","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1253\/circj.69.283","article-title":"Multicenter prospective investigation on efficacy and safety of carperitide for acute heart failure in the 'real world' of therapy","volume":"69","author":"Suwa","year":"2005","journal-title":"Circ J"},{"key":"10.1016\/j.jacbts.2016.10.001_bib52","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1253\/circj.CJ-07-0760","volume":"72","author":"Nomura","year":"2008","journal-title":"Circ J"},{"key":"10.1016\/j.jacbts.2016.10.001_bib53","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1253\/circj.CJ-08-0130","article-title":"Effects of carperitide on the long-term prognosis of patients with acute decompensated chronic heart failure: the PROTECT multicenter randomized controlled study","volume":"72","author":"Hata","year":"2008","journal-title":"Circ J"},{"key":"10.1016\/j.jacbts.2016.10.001_bib54","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1093\/eurheartj\/ehu484","article-title":"Ularitide for the treatment of acute decompensated heart failure: from preclinical to clinical studies","volume":"36","author":"Anker","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacbts.2016.10.001_bib55","first-page":"F615","article-title":"Renal and systemic effects of urodilatin in rats with high-output heart failure","volume":"262","author":"Abassi","year":"1992","journal-title":"Am J Physiol"},{"key":"10.1016\/j.jacbts.2016.10.001_bib56","doi-asserted-by":"crossref","first-page":"R1093","DOI":"10.1152\/ajpregu.00682.2004","article-title":"Equimolar doses of atrial and brain natriuretic peptides and urodilatin have differential renal actions in overt experimental heart failure","volume":"288","author":"Chen","year":"2005","journal-title":"Am J Physiol Regul, Integ Comp Physiol"},{"key":"10.1016\/j.jacbts.2016.10.001_bib57","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/j.1365-2362.1992.tb01427.x","article-title":"Haemodynamic and renal effects of urodilatin bolus injections in patients with congestive heart failure","volume":"22","author":"Kentsch","year":"1992","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.jacbts.2016.10.001_bib58","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.ahj.2005.01.022","article-title":"Effects of the renal natriuretic peptide urodilatin (ularitide) in patients with decompensated chronic heart failure: a double-blind, placebo-controlled, ascending-dose trial","volume":"150","author":"Mitrovic","year":"2005","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacbts.2016.10.001_bib59","doi-asserted-by":"crossref","first-page":"1012.e1","DOI":"10.1016\/j.ahj.2008.02.011","article-title":"Renal effects of ularitide in patients with decompensated heart failure","volume":"155","author":"Luss","year":"2008","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacbts.2016.10.001_bib60","doi-asserted-by":"crossref","first-page":"H777","DOI":"10.1152\/ajpheart.00117.2005","article-title":"Cardiac-specific attenuation of natriuretic peptide A receptor activity accentuates adverse cardiac remodeling and mortality in response to pressure overload","volume":"289","author":"Patel","year":"2005","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.jacbts.2016.10.001_bib61","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1093\/ehjcvp\/pvv040","article-title":"Cenderitide: structural requirements for the creation of a novel dual particulate guanylyl cyclase receptor agonist with renal-enhancing in\u00a0vivo and ex\u00a0vivo actions","volume":"2","author":"Lee","year":"2016","journal-title":"Eur Heart J Cardiovasc Pharm"},{"key":"10.1016\/j.jacbts.2016.10.001_bib62","doi-asserted-by":"crossref","first-page":"19196","DOI":"10.1074\/jbc.M109.010777","article-title":"A\u00a0familial mutation renders atrial natriuretic peptide resistant to proteolytic degradation","volume":"284","author":"Dickey","year":"2009","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jacbts.2016.10.001_bib63","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jacc.2008.02.077","article-title":"Design, synthesis, and actions of a novel chimeric natriuretic peptide: CD-NP","volume":"52","author":"Lisy","year":"2008","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacbts.2016.10.001_bib64","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.jacc.2009.04.080","article-title":"A\u00a0human atrial natriuretic peptide gene mutation reveals a novel peptide\u00a0with enhanced blood pressure-lowering, renal-enhancing, and aldosterone-suppressing actions","volume":"54","author":"McKie","year":"2009","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacbts.2016.10.001_bib65","doi-asserted-by":"crossref","first-page":"11282","DOI":"10.1073\/pnas.0811851106","article-title":"Biodesign of a renal-protective peptide based on alternative splicing of B-type natriuretic peptide","volume":"106","author":"Pan","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jacbts.2016.10.001_bib66","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1172\/JCI116800","article-title":"Vasonatrin peptide: a unique synthetic natriuretic and vasorelaxing peptide","volume":"92","author":"Wei","year":"1993","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jacbts.2016.10.001_bib67","first-page":"515","article-title":"[Comparison of vasorelaxing actions of vasonatrin peptide, C-type natriuretic peptide and atrial natriuretic peptide]","volume":"51","author":"Feng","year":"1999","journal-title":"Sheng li xue bao [Acta Physiol Sinica]"},{"key":"10.1016\/j.jacbts.2016.10.001_bib68","first-page":"187","article-title":"[Vasorelaxing role of vasonatrin peptide in human intramammary artery in\u00a0vitro]","volume":"55","author":"Yu","year":"2003","journal-title":"Sheng li xue bao [Acta Physiol Sinica]"},{"key":"10.1016\/j.jacbts.2016.10.001_bib69","first-page":"252","article-title":"[Comparison of inhibitory effects of three natriuretic peptides on the proliferation of pulmonary artery smooth muscle cells of rats]","volume":"52","author":"Dong","year":"2000","journal-title":"Sheng li xue bao [Acta Physiol Sinica]"},{"key":"10.1016\/j.jacbts.2016.10.001_bib70","doi-asserted-by":"crossref","first-page":"35003","DOI":"10.1074\/jbc.M804538200","article-title":"Novel bifunctional natriuretic peptides as potential therapeutics","volume":"283","author":"Dickey","year":"2008","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jacbts.2016.10.001_bib71","doi-asserted-by":"crossref","first-page":"e52422","DOI":"10.1371\/journal.pone.0052422","article-title":"CD-NP: a novel engineered dual guanylyl cyclase activator with anti-fibrotic actions in the heart","volume":"7","author":"Martin","year":"2012","journal-title":"PloS One"},{"key":"10.1016\/j.jacbts.2016.10.001_bib72","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.yjmcc.2014.08.001","article-title":"Cardiac fibrosis in end-stage human heart failure and the cardiac natriuretic peptide guanylyl cyclase system: regulation and therapeutic implications","volume":"75","author":"Ichiki","year":"2014","journal-title":"J\u00a0Mol Cell Cardiol"},{"key":"10.1016\/j.jacbts.2016.10.001_bib73","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1177\/0091270009336233","article-title":"Pharmacodynamics of a novel designer natriuretic peptide, CD-NP, in a first-in-human clinical trial in healthy subjects","volume":"49","author":"Lee","year":"2009","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.jacbts.2016.10.001_bib74","doi-asserted-by":"crossref","first-page":"e51350","DOI":"10.1371\/journal.pone.0051350","article-title":"Delivery of short interfering ribonucleic acid-complexed magnetic nanoparticles in an oscillating field occurs via caveolae-mediated endocytosis","volume":"7","author":"Lim","year":"2012","journal-title":"PloS One"},{"key":"10.1016\/j.jacbts.2016.10.001_bib75","doi-asserted-by":"crossref","first-page":"e68346","DOI":"10.1371\/journal.pone.0068346","article-title":"Cenderitide-eluting film for potential cardiac patch applications","volume":"8","author":"Ng","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.jacbts.2016.10.001_bib76","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1038\/aps.2015.43","article-title":"Alternative splicing as a biomarker and potential target for drug discovery","volume":"36","author":"Le","year":"2015","journal-title":"Acta Pharmacol Sinica"},{"key":"10.1016\/j.jacbts.2016.10.001_bib77","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","article-title":"A\u00a0randomized trial of intensive versus standard blood-pressure control","volume":"373","author":"Wright","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacbts.2016.10.001_bib78","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1161\/HYPERTENSIONAHA.114.03936","article-title":"Circulating aldosterone and natriuretic peptides in the general community: relationship to cardiorenal and metabolic disease","volume":"65","author":"Buglioni","year":"2015","journal-title":"Hypertension"},{"key":"10.1016\/j.jacbts.2016.10.001_bib79","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.yjmcc.2011.03.013","article-title":"Dendroaspis natriuretic peptide and the designer natriuretic peptide, CD-NP, are resistant to proteolytic inactivation","volume":"51","author":"Dickey","year":"2011","journal-title":"J\u00a0Mol Cell Cardiol"},{"key":"10.1016\/j.jacbts.2016.10.001_bib80","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1161\/HYPERTENSIONAHA.110.159210","article-title":"A\u00a0novel atrial natriuretic peptide based therapeutic in experimental angiotensin II mediated acute hypertension","volume":"56","author":"McKie","year":"2010","journal-title":"Hypertension"},{"key":"10.1016\/j.jacbts.2016.10.001_bib81","doi-asserted-by":"crossref","first-page":"e000206","DOI":"10.1161\/JAHA.113.000206","article-title":"M-atrial natriuretic peptide and nitroglycerin in a canine model of experimental acute hypertensive heart failure: differential actions of 2 cGMP activating therapeutics","volume":"3","author":"McKie","year":"2014","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jacbts.2016.10.001_bib82","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.1016\/j.jash.2016.03.095","article-title":"Aldosterone levels, atrial natriuretic peptide and resistant hypertension in the general community","volume":"10","author":"Buglioni","year":"2016","journal-title":"J\u00a0Am Soc Hyperten"},{"key":"10.1016\/j.jacbts.2016.10.001_bib83","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1016\/j.jash.2016.03.051","article-title":"A\u00a0first-in-human trial of a novel designer natriuretic peptide ZD100 in human hypertension","volume":"10","author":"Chen","year":"2016","journal-title":"J\u00a0Am Soc Hyperten"}],"container-title":["JACC: Basic to Translational Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452302X16301577?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452302X16301577?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:18:40Z","timestamp":1762820320000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2452302X16301577"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":83,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["S2452302X16301577"],"URL":"https:\/\/doi.org\/10.1016\/j.jacbts.2016.10.001","relation":{},"ISSN":["2452-302X"],"issn-type":[{"value":"2452-302X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Innovative Therapeutics","name":"articletitle","label":"Article Title"},{"value":"JACC: Basic to Translational Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacbts.2016.10.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}